Barclays has reaffirmed its equal weight rating for uniQure (QURE). The move reflects a continuation of the firm's existing stance on the biotechnology company.
- Barclays maintains equal weight rating
- uniQure (QURE) is the subject of the rating
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.
Share this article